Clinigen Group Named Business of the Year at the European Business Awards

Home » Clinigen Group Named Business of the Year at the European Business Awards

Clinigen Group Named Business of the Year at the European Business Awards

award-winnerClinigen Group plc, the specialty global pharmaceutical company, has been named the winner of the Business of the Year Award with Turnover of €26-150 million at the 2014/15 European Business Awards Gala Ceremony in London.

Peter George, Chief Executive Officer, Clinigen Group said: “I am immensely proud that Clinigen has been recognized as Business of the Year across all of Europe. This is a huge achievement and testament to how far the Group has come over the last year as we continue in our mission to deliver the right drug to the right patient at the right time.”

Clinigen was one of only 10 companies in Europe to be shortlisted for the Business of the Year with Turnover of €26-150 million category and one of 11 overall category winners out of more than 20,000 applicants from 33 countries.

The Group has been previously been named as one of more than 700 European ‘National Champions’ by a judging panel consisting of European business and political leaders, academics and entrepreneurs. It was also recognized by the European Business Awards as one of only 110 Ruban d’Honneur finalists in February.

Adrian Tripp, CEO of the European Business Awards said: “Our winners are shaping the face of European business and helping keep Europe’s position as a leading player on the global business stage. Huge congratulations to Clinigen Group for their success.”

The Business of the Year Award recognizes companies that successfully demonstrate financial returns, strong growth, innovation and market leadership in their sectors. In 2011 Clinigen was named the fastest growing company in the UK by the Sunday Times Virgin Fast Track 100. The Group joined the London Stock Exchange’s AIM in September 2012, the first UK healthcare company to list in London in five years, and won Best Newcomer at the AIM Awards in 2013. In April 2015, Clinigen acquired Idis, creating the market leader in the ethical unlicensed supply of medicines.

Clinigen has seen six-fold revenue growth over the past 4 years and has increased profit margins from 8% to 20%. The group is committed to best practice and operating as an award-winning company.